Scarica l'app Stockscreener
8.20
0.24%
-0.02
Pre-mercato:
8.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.22
Aprire:
$8.2
Volume 24 ore:
1.16M
Relative Volume:
0.56
Capitalizzazione di mercato:
$574.64M
Reddito:
-
Utile/perdita netta:
$-30.04M
Rapporto P/E:
-5.1899
EPS:
-1.58
Flusso di cassa netto:
$-27.38M
1 W Prestazione:
-1.20%
1M Prestazione:
+4.19%
6M Prestazione:
+406.17%
1 anno Prestazione:
+245.99%
Intervallo 1D:
$8.16
$8.24
Intervallo di 1 settimana:
$8.025
$8.32
Portata 52W:
$0.8301
$8.345
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Nome
Regulus Therapeutics Inc
Settore
Industria
Telefono
858-202-6300
Indirizzo
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Confronta RGLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
8.20 | 574.64M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-27 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-08-02 | Iniziato | Oppenheimer | Outperform |
| 2024-03-18 | Iniziato | Leerink Partners | Outperform |
| 2018-03-28 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | Iniziato | Leerink Partners | Outperform |
| 2017-06-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-06 | Reiterato | Wedbush | Outperform |
| 2017-01-30 | Downgrade | Needham | Buy → Hold |
| 2017-01-30 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-11-02 | Reiterato | Needham | Buy |
| 2016-07-25 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | FBR Capital | Outperform |
| 2016-06-28 | Reiterato | Needham | Buy |
| 2016-06-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-04-13 | Iniziato | Chardan Capital Markets | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2015-04-21 | Ripresa | FBR Capital | Outperform |
| 2014-11-24 | Iniziato | Deutsche Bank | Buy |
| 2014-08-07 | Reiterato | FBR Capital | Outperform |
| 2013-08-14 | Reiterato | Needham | Buy |
Mostra tutto
Regulus Therapeutics Inc Borsa (RGLS) Ultime notizie
Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulu - GuruFocus
Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS) - GuruFocus
Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (NASDAQ:RGLS) - Seeking Alpha
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis - GlobeNewswire Inc.
Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows - Fierce Pharma
Novartis arm commences tender offer to buy Regulus Therapeutics - Medical Dialogues
Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined - Endpoints News
Novartis announces commencement of tender offer to acquire Regulus Therapeutics - The Manila Times
Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics - marketscreener.com
Novartis Launches Tender Offer for Regulus Therapeutics Takeover - marketscreener.com
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView
Latham and Covington Advise on Novartis’s Acquisition of Regulus - Law Street Media
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com - Defense World
Regulus Therapeutics to be Acquired by Novartis - TipRanks
Regulus: Q1 Earnings Snapshot - Norwalk Hour
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway - GuruFocus
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Renaissance Technologies LLC - Defense World
Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com
What is Leerink Partnrs’ Estimate for RGLS Q1 Earnings? - Defense World
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN
Taxation With Representation: Goodwin, Haynes Boone - Law360
Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - MSN
Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize
Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus
Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus
Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha
New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com
Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare
Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN
Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus
Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus
Regulus Therapeutics Inc Azioni (RGLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):